Notal Vision
Total Raised
$89MInvestors Count
5Deal Terms
1Funding, Valuation & Revenue
4 Fundings
Notal Vision has raised $89M over 4 rounds.
Notal Vision's latest funding round was a Series D for $60M on June 7, 2021.
Notal Vision's valuation in January 2003 was $8M.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
6/7/2021 | Series D | $60M | 1 | |||
12/11/2019 | Series C | |||||
1/28/2003 | Series A | |||||
1/28/2003 | Series B | $8M |
Date | 6/7/2021 | 12/11/2019 | 1/28/2003 | 1/28/2003 |
|---|---|---|---|---|
Round | Series D | Series C | Series A | Series B |
Amount | $60M | |||
Investors | ||||
Valuation | $8M | |||
Revenue | ||||
Sources | 1 |
Notal Vision Deal Terms
1 Deal Term
Notal Vision's deal structure is available for 1 funding round, including their Series B from January 28, 2003.
Round | Series B |
|---|---|
Funding Date | |
Pre-Money Valuation | |
Post-Money Valuation | |
Amount Raised | |
Shares Authorized | |
Issuance Price | |
Dividend Rate | |
Liquidation Preferences | |
Liquidation Price | |
Participation | |
Conversion Price | |
Anti Dilution | |
General Voting | |
Board Voting | |
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series B |
Notal Vision Investors
5 Investors
Notal Vision has 5 investors. Ganot Capital invested in Notal Vision's Series D funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
12/11/2019 | 6/7/2021 | 2 Series C, Series D (2021) | Family Office | Israel | ||
Private Equity | Connecticut | |||||
Venture Capital | Israel | |||||
Venture Capital | Israel | |||||
Venture Capital | Israel |
First funding | 12/11/2019 | ||||
|---|---|---|---|---|---|
Last Funding | 6/7/2021 | ||||
Investor | |||||
Rounds | 2 Series C, Series D (2021) | ||||
Board Seats | |||||
Type | Family Office | Private Equity | Venture Capital | Venture Capital | Venture Capital |
Location | Israel | Connecticut | Israel | Israel | Israel |
Compare Notal Vision to Competitors
Verana Health operates as a digital health company focused on the analysis and management of real-world data in the healthcare sector. The company provides insights and analytics from a network of healthcare clinicians, addressing drug lifecycle management and medical practice optimization. Verana Health's services support clinical research and adherence to quality measures. Verana Health was formerly known as Digisight Technologies. It was founded in 2008 and is based in San Francisco, California.
Macuject operates as a digital health company that focuses on preventing blindness, specifically in the domain of age-related macular degeneration (AMD). It offers a cloud-based software platform that uses artificial intelligence to assist healthcare professionals in diagnosing AMD, optimizing treatment plans, and monitoring disease progression. It primarily serves the healthcare industry, particularly clinicians treating wet AMD. It was founded in 2017 and is based in Kew, Australia.
Siloton focuses on integrated photonics technology in the medical sector, specifically in ophthalmology. The company is developing a remote monitoring service for age-related macular degeneration (AMD) that aims to provide treatment to patients and prevent vision loss. This service integrates a diagnostic imaging device with cloud-based digital health tools. It was founded in 2020 and is based in Bristol, United Kingdom.
Ikerian focused on healthcare data analysis and decision support. The company offers a modular healthcare software platform that organizes and analyzes multimodal data to provide insights for disease understanding, patient matching, and outcome prediction. Its solutions cater to pharmaceutical companies, device manufacturers, clinics, hospitals, contract research organizations, and research institutions. Ikerian was formerly known as RetinAI Medical. It was founded in 2017 and is based in Bern, Switzerland. In October 2025, Ikerian was acquired by EssilorLuxottica.
visotec is a medical device company that develops Optical Coherence Tomography diagnostics devices (OCT) for Age-Related Macular Degeneration (AMD) patients. Its product helps in the home-based diagnosis of retina analysis. The company was founded in 2019 and is based in Lubeck, Germany. In May 2023, visotec was acquired by Heidelberg Engineering. The terms of the transaction were not disclosed.
Loading...